Oligomerix, Inc. to Present Data on Lead Alzheimer’s Disease Candidate at Neuroscience 2019

NEW YORK--(BUSINESS WIRE)-- OLIGOMERIX, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, will present preclinical data on its lead product candidate at Neuroscience 2019, the 49^th annual conference of the Society for Neuroscience, being held in Chicago from October 19-23.

In an oral presentation, James Moe, Ph.D., MBA, President and CEO of Oligomerix® will discuss the results of in vitro and in vivo studies with its small molecule tau inhibitor.

Presentation Details:

Date: October 22, 2019
Time: 10:00 am – 10:15 am
Location: McCormick Place, Room S103
Title: Selection of a small molecule tau oligomer inhibitor for IND enabling studies
Session Type/Number: Nanosymposium/447

There is a critical unmet need for disease-modifying drugs for AD and related dementias, and the role tau plays in the disease has become an important target for drug discovery and development. Oligomerix and other research labs have shown that tau oligomers are directly neurotoxic, inhibit signal transmission between neurons, and impair formation of memory in mice. Oligomerix’s core technology is focused on developing small molecule inhibitors of tau self-association, the initial step in the formation of pathological tau oligomers at the beginning of the tau aggregation cascade. Oligomerix’s lead compound has demonstrated efficacy in preclinical studies, and preclinical safety studies are in progress. A complementary mechanistic biomarker is being developed to facilitate clinical development.

About Oligomerix, Inc.

Oligomerix is an emerging biotechnology company focused on discovering and developing novel, small-molecule inhibitors of tau oligomer formation for Alzheimer’s disease (AD) and related neurodegenerative diseases with tau pathology. Oligomerix’s drug discovery platform has identified a pipeline of novel, small molecule lead compounds that are designed to inhibit tau oligomer formation at the beginning of the aggregation process, and the company has achieved proof-of-concept in an animal model best representing tau aggregation in AD. IND-enabling studies are in process for the company’s lead program targeting AD. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine and has received considerable support from the National Institute on Aging of the National Institutes of Health (NIH). Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit http://www.oligomerix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191016005277/en/